Day: May 4, 2020

Paris – La Défense, le 4 mai 2020 : Depuis le 29 avril 2020, Tarkett est victime d’une cyberattaque affectant une partie de ses opérations, malgré les mesures de sécurité informatique mises en place par le Groupe. En réponse, le Groupe a immédiatement arrêté ses systèmes d’information et mis en place les mesures préventives nécessaires visant à protéger ses opérations, ainsi que les données de ses collaborateurs, clients et partenaires.Les équipes Tarkett sont pleinement mobilisées et accompagnées d’experts informatiques et d’investigation indépendants mondialement reconnus pour permettre un retour à la normale des opérations le plus rapidement possible. Les activités commerciales et la production restent perturbées.Tarkett est en contact avec les autorités compétentes et a avisé son assureur en cybersécurité. Tarkett fera des nouveaux...

Alexis RIDEAU has recognized experience in the development, negotiation and implementation of strategic partnerships in the life sciences field, particularly in microbiology applied to health and infectious diseases.He also has a good track record in sector analysis, support for innovation funding, and fundraising.DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics and nutrition, announces the appointment of Alexis RIDEAU as CEO, effective May 1, 2020.Prior to joining DEINOVE, Alexis RIDEAU was in charge of developing industrial relations and coordinating the strategic partnership team at BIOASTER (Lyon/Paris), a Technology Research Institute in applied microbiology, which specializes in the design and use of technology...

The Management Board of PLLC Kauno Energija (hereinafter – the Company) (code – 235014830) assessed the results of Company’s business activity of the 1 quarter of the year 2020 and financial state as at March 31, 2020 and approved PLLC Kauno Energija consolidated and Company’s non-audited results of the 1 quarter of the year 2020.The result of Company’s business activities of the 1 quarter of the year 2020 according to the International Financial Reporting Standards is profit (before taxes) in amount of EUR 1,901 thousand (the profit of the 1 quarter of the year 2019 was EUR 4,631 thousand), turnover from sales is EUR 20,214 thousand (in the 1 quarter of the year 2019 it was EUR 28,372 thousand). The profit of the Group which consists of PLLC Kauno Energija and its’ subsidiaries LLC Kauno Energija NT (code – 303042623) and LLC Petrašiūnų...

AB „Kauno energija“ (toliau – Bendrovė) (įm. kodas 235014830) valdyba įvertino Bendrovės 2020 m. I ketvirčio ūkinės veiklos rezultatus ir finansinę padėtį 2020 m. kovo 31 dienai ir pritarė AB „Kauno energija“ konsoliduotiesiems ir Bendrovės 2020 m. I ketvirčio neaudituotiems ūkinės veiklos rezultatams.Bendrovės 2020 m. I-o ketvirčio veiklos rezultatas pagal Tarptautinius finansinės atskaitomybės standartus yra pelnas (prieš apmokestinimą) – 1 901 tūkst. Eur (2019 m. I-o ketvirčio pelnas – 4 631 tūkst. EUR), pardavimų pajamos – 20 214 tūkst. Eur (2019 m. I-ą ketvirtį – 28 372 tūkst. EUR), o Grupės, kurią sudaro AB „Kauno energija“ bei jos patronuojamos bendrovės – UAB „Kauno energija NT“ (įm. kodas 303042623) ir UAB „Petrašiūnų katilinė“ (įm. kodas 304217723), pelnas (prieš apmokestinimą) – 2 228 tūkst. Eur (2019 m. I-o ketvirčio pelnas...

GHENT, Belgium, May 04, 2020 (GLOBE NEWSWIRE) — Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces the appointment of Oliver Gödje, MD, PhD, as Chief Medical Officer, with immediate effect. Dr Gödje replaces Gijs Klarenbeek, MD, who remains with Sequana Medical as Senior Medical Advisor.Dr Gödje is a highly experienced clinician and medtech industry executive with 18 years of international experience in medical and commercial roles. Prior to joining Sequana Medical, Dr Gödje served as Chief Medical Officer at Humedics GmbH, Medical Director and VP Sales & Marketing at Hepa Wash GmbH, and Medical & Marketing Director of PULSION Medical Systems AG, all medtech companies in the liver or cardiovascular field....

UAB Ignitis Grupė, (hereinafter – the Company, Ignitis Group) identification code 301844044, registered office placed at Žvejų str. 14, Vilnius, Republic of Lithuania. The total nominal value of issued bonds 600 000 000 EUR; ISIN codes XS1646530565; XS1853999313.Ignitis Group invites shareholders of the companies of the Group, bondholders, investors, analysts and other stakeholders to join its investor conference webinar scheduled on the May 7, 2020 at 4.00 pm (EET). The presentation will be held in English.The webinar will be hosted by the General Manager and the Chairman of the Board of Ignitis group Mr. Darius Maikštėnas as well as the Director of Finance and Treasury Mr. Darius Kašauskas, who will introduce the Ignitis Group financial results for the year 2019 and will answer the participant questions.After the presentation investors...

UAB „Ignitis grupė“ (toliau – „Ignitis grupė“ ir Bendrovė), juridinio asmens kodas: 301844044, registruotos buveinės adresas: Žvejų g. 14, Vilnius. Bendra UAB „Ignitis grupė“ išleistų obligacijų nominali vertė 600 000 000 EUR; ISIN kodai: XS1646530565; XS1853999313.„Ignitis grupė“ kviečia grupės įmonių akcininkus, obligacijų savininkus, investuotojus, analitikus ir visus besidominčius į grupės 2019 metų audituotų finansinių rezultatų pristatymą internetiniame seminare (angl. „webinar“). Pradžia – 2020 m. gegužės 7 d. 16.00 val. Seminaras vyks anglų kalba.„Ignitis grupės“ generalinis direktorius ir valdybos pirmininkas Darius Maikštėnas bei finansų ir iždo direktorius Darius Kašauskas pakomentuos „Ignitis grupės” 2019 metų audituotus finansinius veiklos rezultatus ir po pristatymo atsakys į dalyvių klausimus.Dėl riboto seminarui skirto...

Schlieren/Switzerland, 4 May 2020  Consent received from lenders for a precautionary amendment of financial covenantsLiquidity in excess of €385m at 30 April up from €360m at 24 MarchDecisive actions taken to maximise cash and reduce costsAttachmentRelease

Highlights of the quarterOur market share in capacitive sensors for mobile phones increased year-on-year. Several smartphone models were launched with the latest generation of sensors from Fingerprints.Revenues in the first quarter of 2020 were affected by capacity limitations among subcontractors and restrictions on goods transportation as a result of the coronavirus outbreak.Our offering in Payments & Access was strengthened during the quarter through, among other activities, the launch of a further development of our biometric software platform.First quarter of 2020Revenues amounted to SEK 310.0 M (342.9)The gross margin was 24 percent (23)EBITDA totaled SEK 11.6 M (35.8)The operating result was negative SEK 17.7 M (neg: 1.9)Earnings per share before dilution were negative SEK 0.01 (neg: 0.01)Cash flow from operating activities...

Kort om kvartaletVår marknadsandel inom kapacitiva sensorer för mobiltelefoner har ökat sedan motsvarande kvartal förra året. Flera smartphonemodeller lanserades med den senaste generationens sensorer från Fingerprints.Omsättningen i det första kvartalet 2020 påverkades av kapacitetsbegränsningar hos underleverantörer och inskränkningar i varutransporter till följd av coronavirusutbrottet.Vårt erbjudande inom Payments & Access stärktes under kvartalet, bland annat genom lanseringen av en vidareutvecklad version av vår biometriska mjukvaruplattform.Första kvartalet 2020Intäkterna uppgick till 310,0 Mkr (342,9)Bruttomarginalen uppgick till 24 % (23)EBITDA uppgick till 11,6 Mkr (35,8)Rörelseresultatet uppgick till -17,7 Mkr (-1,9)Resultat per aktie före utspädning uppgick till -0,01 kr (-0,01)Kassaflödet från den löpande verksamheten...